Bacterial Vaginosis Treatment Guidelines

Efficacy of Oral and Vaginal Treatments

The Centers for Disease Control and Prevention (CDC) guidelines demonstrate that oral and vaginal treatments have equivalent efficacy (78-87% cure rate) and should be used as alternatives, not simultaneously 1, 2
Metronidazole oral 500 mg twice a day for 7 days achieves a cure rate of 84% 2
Metronidazole gel vaginal 0.75% (one full applicator intravaginally once a day for 5 days) achieves a cure rate of 75% 2
Clindamycin vaginal cream 2% (one full applicator at bedtime for 7 days) achieves a cure rate of 82% 1
Randomized controlled trials show no significant differences between oral and vaginal treatments (78% vs. 82% respectively) 2

The oral route is preferred when the patient is at high risk of pregnancy (with a history of preterm labor) 1, 2
The oral route is preferred when maximum adherence is required with a single dose of metronidazole 2g (although it has lower efficacy of 84%) 2
The vaginal route is preferred when the patient cannot tolerate systemic effects (gastrointestinal discomfort, unpleasant taste) 1, 2
The vaginal route is preferred when there is intolerance to oral metronidazole but not a true allergy 1, 2
The vaginal route is preferred when serum concentrations of intravaginal metronidazole are less than 2% of standard oral doses, minimizing systemic effects 1, 2

Patients should avoid alcohol during treatment and for 24 hours after to prevent a disulfiram-like reaction 2
Patients with an allergy to oral metronidazole should not receive metronidazole vaginally 1, 2
Clindamycin cream is oil-based and can weaken latex condoms and diaphragms 2
Clindamycin cream should not be used during pregnancy (two randomized studies showed an increased risk of preterm labor) 1

Routine treatment of male sexual partners is not recommended, as clinical studies demonstrate that it does not affect treatment response or recurrence rates 1, 2

Follow-up visits are unnecessary if symptoms resolve 1, 2
Recurrence of bacterial vaginosis is not unusual, and alternative regimens can be used to treat recurrent disease 1, 2

The Centers for Disease Control and Prevention recommends that Chlamydia trachomatis requires intracellular-acting antibiotics that can penetrate host cells where the organism resides 3, 4
First-line agents for Chlamydia are azithromycin 1g orally as a single dose OR doxycycline 100mg orally twice daily for 7 days, as suggested by the Centers for Disease Control and Prevention 3, 4, 5

The Centers for Disease Control and Prevention suggests that BV requires anaerobic coverage to address the polymicrobial overgrowth of Gardnerella vaginalis and other anaerobes 6, 7
First-line treatment for BV is metronidazole 500mg orally twice daily for 7 days, with a 95% cure rate, as recommended by the Centers for Disease Control and Prevention 6, 7

The Centers for Disease Control and Prevention recommends treating both conditions simultaneously with separate medications rather than attempting monotherapy 3, 4
For Chlamydia, the preferred treatment is azithromycin 1g orally as a single dose, due to its high compliance rate 3, 4
For BV, the recommended treatment is metronidazole 500mg orally twice daily for 7 days, due to its high efficacy 6, 7, 8

Patients should be advised to avoid alcohol during metronidazole treatment and for 24 hours after completion to prevent disulfiram-like reactions, as recommended by the Centers for Disease Control and Prevention 6, 7, 8
Patients should be instructed to abstain from sexual intercourse for 7 days after Chlamydia treatment or until completion of therapy, as suggested by the Centers for Disease Control and Prevention 3, 4

For Chlamydia, sex partners must be treated to prevent reinfection, as recommended by the Centers for Disease Control and Prevention 3, 4, 5
For BV, routine treatment of male sex partners is not recommended, as it does not influence treatment response or recurrence rates, according to the Centers for Disease Control and Prevention 6, 7, 9